Research

Hormonal

Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a statistically significant increase in the dispensing of antidepressants, suggesting a potential adverse effect on mood or mental health.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Trulicity), be aware that there is a statistically higher chance you might be prescribed an antidepressant. This does not mean everyone will experience mood issues, but it is a known risk signal. Monitor your mental health closely, especially if you have a history of depression, and discuss any mood changes with your doctor immediately.

ModerateSupportsMEDIUM confidence
Individuals exposed to GLP-1 receptor agonists are at greater risk of being dispensed antidepressants. The possible impact of GLP-1 receptor agonists on the mood of consumers requires ongoing vigilance and further research.
Osvaldo P. Almeida et al. · Diabetes Obesity and Metabolism · 2024

Why this rating

Observational data (cross-sectional, case-control, longitudinal) with large sample size but inherent limitations regarding causality, confounding (e.g., diabetes severity), and prescription bias.

Source

Cross‐sectional, case‐control and longitudinal associations between exposure to glucagon‐like peptide‐1 receptor agonists and the dispensing of antidepressants

Osvaldo P. Almeida et al. · Diabetes Obesity and Metabolism · 2024

DOI 10.1111/dom.15616

cohort · n=1746391Cited 15×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →